ArticleClinical journal of gastroenterology2026
A case of complete remission of multiple lung metastases following surgical resection of huge hepatocellular carcinoma invading the colon and postoperative treatment with atezolizumab and bevacizumab.
Article in Clinical journal of gastroenterology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We report a rare case of giant hepatocellular carcinoma (HCC) with direct invasion to the colon and synchronous multiple lung metastases that achieved complete remission with surgical hepatectomy followed by chemotherapy with atezolizumab and bevacizumab. An 80-year-old man presented with abdominal distension and appetite loss. Imaging studies demonstrated a large HCC protruding from the liver with compression and invasion of the ascending colon, accompanied by multiple bilateral pulmonary nodules. To relieve symptoms and reduce the risk of tumor rupture, upfront surgical resection consisting of right hepatectomy and right hemicolectomy was performed. Histopathological examination revealed moderately to poorly differentiated HCC with direct invasion into the ascending colon and microscopic portal vein invasion. Postoperatively, tumor markers initially decreased; however, subsequent elevation led to initiation of atezolizumab plus bevacizumab for treatment of pulmonary metastases. Tumor markers subsequently normalized, and follow-up computed tomography demonstrated disappearance of all pulmonary metastases, with only scar-like lesions remaining. Radiologic complete remission was achieved 14 months after hepatectomy. The patient remains alive without recurrence 54 months after surgery. Direct invasion of HCC into adjacent organs is extremely rare and is generally associated with poor prognosis. The role of systemic chemotherapy after reduction surgery for advanced HCC remains controversial. Although this is a single case experience and caution is needed when generalizing, this case suggested that combined treatment with initial resection of the primary tumor followed by immunotherapy for remnant lesions could be feasible in selected patients and would potentially contribute to symptom relief and control of metastatic lesions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.